Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues
Authors:
- G. GuaraldiGGG. Guaraldi
- S. ZonaSZS. Zona
- A. CossarizzaACA. Cossarizza
- L. VernacotolaLVL. Vernacotola
- F. CarliFCF. Carli
- A. LattanziALA. Lattanzi
- B. BeghettoBBB. Beghetto
- G. OrlandoGOG. Orlando
- S. De BiasiSBS. De Biasi
- R. TerminiRTR. Termini
- M. GarauMGM. Garau
- 1 August 2013
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 14 (4) , 140-148
Abstract
Background: We performed a study to evaluate change in cardiometabolic and endothelial function in HIV-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy versus triple therapy. Methods: The MONARCH trial recruited 30 patients who were taking triple combination therapy and with HIV RNAP > .05), with no statistically significant difference between arms (10.7% at baseline and 6.7% at week 48 in the DRV/r + 2 NRTIs arm; 11.1% at baseline and 8.8% at week 48 in the DRV/r arm). The changes at week 48 were similar in the 2 arms for EPCs and CECs. Total cholesterol and low-density lipoprotein (LDL) cholesterol showed larger rises to week 48 in the DRV/r arm monotherapy group than in the triple-therapy group (+26 vs +9 mg/dL for total cholesterol and +14 vs +5 mg/dL for LDL cholesterol). Conclusions: In the MONARCH trial, switching from triple combination treatment to DRV/r, with or without nucleoside analogues, did not translate into clinically meaningful reductions in endothelial function as measured by FMD.Keywords
This publication has 22 references indexed in Scilit:
- CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumptionAIDS, 2011
- Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS, 2010
- Relationship of Body Composition, Metabolic Status, Antiretroviral Use, and HIV Disease Factors to Endothelial Dysfunction in HIV-Infected SubjectsAIDS Research and Human Retroviruses, 2010
- Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapyAIDS, 2010
- Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkersHIV Medicine, 2010
- Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patientsAIDS, 2009
- Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral TherapyJACC, 2008
- Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk FactorsCirculation, 2008
- Endothelial Function in HIV-Infected PersonsClinical Infectious Diseases, 2006
- Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD responseEuropean Heart Journal, 2004